Member Info for Laura2022

Hi hopist

£500k of contracts from July -Dec 2024 to be carried forward (stronger second half of the year mentioned in today's RNS)

Cash now of £700,000 v market cap £1.3mln

Charts most oversold in 12mths

Dosing tool nearly ready "final sprint"

Late stage contract

A.I medicine

TR1 buyer suggested adding more in new ISA

Now volume quiet it means the 100-200k buy backs will have very positive impact

Eg current volume 770k volume and by end of day TIG share buy backs will be large chunk

Bid price very strong

In

15 green boxes

Wow

Another 2mln+ to buy Lukeee

£500k of contracts from July -Dec 2024 to be carried forward

Cash now of £700,000 v market cap £1.3mln

Charts most oversold in 12mths

Dosing tool nearly ready "final sprint"

Late stage contract

A.I medicine

TR1 buyer suggested adding more in new ISA

Bunsen

You're so bitter everywhere you go

I've personally been buying NARF for 3 weeks as shown in my posts

Huge

Hence why I was buying

60p+ in no time at this rate

I'd expect some RNS during remainder of March

The Company is actively progressing a number of late-stage opportunities, however, there is no guarantee that these contracts will be signed within the current financial year.

KingHomerJ

Posts: 1,730

Price: 0.485

No Opinion

Potential Value...1 Mar 2025 14:11

The potential commercial value of personalized dosing software, like Physiomics plc's PREDICT-ONC, is significant due to the growing demand for precision medicine in oncology. Below are key areas where this technology can generate revenue and market value:

1. Market Demand & Growth Potential

• Global Oncology Market: Expected to reach $500+ billion by 2030, with a strong focus on personalized medicine.

There's about £500k of contracts to be carried over into this H2

Now 170k, up again

on 5 March 2025 it purchased 170,795 ordinary shares of £0.001 each in the Company (the "Repurchased Shares"

"Final sprint "

date, implementation of the dosing software onto the DoseMeRx platform is undergoing its final sprint, with minor bugs being addressed following several internal evaluation cycles. The Company is exploring a deeper relationship with DoseMe to develop additional models to be implemented on their platform.

Cssh now half the market capitalisation

finished the half year with £269k of cash and cash equivalents. Post the period end, on 17 February 2025, the Company completed a placing and retail offer of £500k which added to the cash runway.

Chairman and CEO's Business Strategy Update

The Directors are pleased that the Company is on track to meet market expectations, which, if achieved, would mean an increase of approximately 31% in total income compared with the financial year ended 30 June 2024, driven by a stronger second half of the current financial year. The Company continues to make progress in building its Modelling and Simulation pipeline, contracting a broadening range of projects. In addition to driving new client business, three of our long-standing clients signed new contracts with us within the period, reflecting the quality of work the Company provides its clients and their desire to continue receiving our support. The last six months has seen the launch of the Company's new Biostatistics service-line and implementation of Personalised Medicine Dosing Software on the DoseMeRx platform.

Good point Lukee

Just click on his posts last 3mtths

Another one not be trusted and with agendas

Make your mind up Dartron

Yesterday you said hold till AGM

I'm beginning to think it's another to be filtered

Dartron

Posted in: TIG

Posts: 2,854

Price: 53.60

No Opinion

RE: Management4 Mar 2025 17:30

Last years AGM was Thursday, 18 April so not long to wait. BOD will be under immense pressure.

Definitely worth holding until the AGM and see what occurs. Perhaps even a strategic revue?

I think this will be their latest one

05-Mar-2516:35:0554.8099,797